Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...
The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...
Richard Schilsky, MD, touched on the research driving ASCO to award “Advance of the Year” to molecular profiling in gastrointestinal cancers, and what the...
Nivolumab (Opdivo) plus ipilimumab (Yervoy) and 2 cycles of chemotherapy provided superior overall survival (OS) results compared with chemotherapy alone as well as a...
A study published in JAMA Network Open highlighted the conflicting opinions of oncologic health care professionals regarding telehealth and gave insight into potential barriers...
The FDA has accepted and granted priority review to a supplemental new drug application (sNDA) for the first-in-class JAK1/JAK2 inhibitor ruxolitinib (Jakafi) for the...
Results from the ongoing KEYNOTE-799 study (NCT03631784) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) Singapore demonstrated promising safety and efficacy...
The FDA granted fast track designation to a DNA-mediated interleukin-12 (IL-12) immunotherapy, GEN-1, to treat patients with advanced ovarian cancer, according to a press...
The FDA has approved the PD-1 inhibitor cemiplimab-rwlc (Libtayo) as a first-line treatment option for patients with locally advanced or metastatic non–small cell lung...
AstraZeneca announced it has voluntarily withdrawn the indication for durvalumab (Imfinzi) in previously treated adult patients with locally advanced or metastatic bladder cancer in...
Adjuvant pazopanib (Votrient) treatment did not positively impact overall survival (OS) rates following resection in patients with locally advanced renal cell carcinoma (RCC), according...
An analysis of tivozanib versus sorafenib in patients with advanced renal cell carcinoma (RCC) included in the phase 3 TIVO-3 study revealed that, as...
The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...
In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...
A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...
An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in...
